Utility of novel androgen receptor therapies in the real world: A nuanced approach

Mallika Dhawan; Charles J. Ryan

doi:10.1016/j.urolonc.2016.05.002

Utility of novel androgen receptor therapies in the real world: A nuanced approach

Mallika Dhawan, Charles J. Ryan

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Abiraterone and enzalutamide are in widespread clinical use because of their favorable safety and efficacy. Nonetheless, even with newer agents, resistance develops overtime. In this review, we discuss mechanisms of resistance to these newer agents as well as novel therapeutic agents. We also review the literature to help clinicians decide which agent to begin with and when to stop or switch androgen receptor agents.

Original language	English (US)
Pages (from-to)	340-347
Number of pages	8
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	34
Issue number	8
DOIs	https://doi.org/10.1016/j.urolonc.2016.05.002
State	Published - Aug 1 2016
Externally published	Yes

Keywords

Androgen receptor therapies
Novel therapies
Prostate cancer
Resistance mechanisms

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.urolonc.2016.05.002

Find It

Find It at U of M Libraries

Cite this

@article{91fc213b40a841e7ad291df40e2e7546,

title = "Utility of novel androgen receptor therapies in the real world: A nuanced approach",

abstract = "Abiraterone and enzalutamide are in widespread clinical use because of their favorable safety and efficacy. Nonetheless, even with newer agents, resistance develops overtime. In this review, we discuss mechanisms of resistance to these newer agents as well as novel therapeutic agents. We also review the literature to help clinicians decide which agent to begin with and when to stop or switch androgen receptor agents.",

keywords = "Androgen receptor therapies, Novel therapies, Prostate cancer, Resistance mechanisms",

author = "Mallika Dhawan and Ryan, {Charles J.}",

year = "2016",

month = aug,

day = "1",

doi = "10.1016/j.urolonc.2016.05.002",

language = "English (US)",

volume = "34",

pages = "340--347",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "8",

}

TY - JOUR

T1 - Utility of novel androgen receptor therapies in the real world

T2 - A nuanced approach

AU - Dhawan, Mallika

AU - Ryan, Charles J.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Abiraterone and enzalutamide are in widespread clinical use because of their favorable safety and efficacy. Nonetheless, even with newer agents, resistance develops overtime. In this review, we discuss mechanisms of resistance to these newer agents as well as novel therapeutic agents. We also review the literature to help clinicians decide which agent to begin with and when to stop or switch androgen receptor agents.

AB - Abiraterone and enzalutamide are in widespread clinical use because of their favorable safety and efficacy. Nonetheless, even with newer agents, resistance develops overtime. In this review, we discuss mechanisms of resistance to these newer agents as well as novel therapeutic agents. We also review the literature to help clinicians decide which agent to begin with and when to stop or switch androgen receptor agents.

KW - Androgen receptor therapies

KW - Novel therapies

KW - Prostate cancer

KW - Resistance mechanisms

UR - http://www.scopus.com/inward/record.url?scp=84979582660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979582660&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2016.05.002

DO - 10.1016/j.urolonc.2016.05.002

M3 - Review article

C2 - 27450893

AN - SCOPUS:84979582660

SN - 1078-1439

VL - 34

SP - 340

EP - 347

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 8

ER -

Utility of novel androgen receptor therapies in the real world: A nuanced approach

Abstract

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this